To analyze the clinical data of 69 patients with primary lung cancer mediated malignant pleural effusion (MPE) and explore the therapeutic effects and adverse reactions of endostar and cisplatin in the treatment of lung cancer mediated MPE through intrapleural injection.

The clinical data of 69 patients with lung cancer mediated MPE in our hospital from 2016 to June 2018 were collected for this study. They were divided into two groups according to the therapeutic regimen: 23 cases were treated with endostar (30 mg through intrapleural injection, twice a week) and the rest 46 cases were treated with cisplatin (30 mg/m² through intrapleural injection, twice a week). The curative effects and adverse reactions of the two groups were observed and analyzed.

The objective response rate (ORR) was 56.5% in the endostar group, which was significantly higher than that in the cisplatin group (26.1%, P<0.05). Stratified analysis showed that in the patients with bloody pleural effusion, the ORRs were 88.9% in the endostar group and 5% in the cisplatin group, and the difference was statistically significant between the two groups (P<0.05). In the patients with non-bloody pleural effusion, the ORRs were 35.7% in the endostar group and 42.3% in the cisplatin group. In the patients with lower carcinoembryonic antigen (CEA) values (<100 μg/L) in the pleural effusion, the ORRs were 53.8% in the endostar group and 8.3% in the cisplatin group, and statistical significant difference was found between the two groups (P<0.05). In the patients with higher CEA values (>100 μg/L) in the pleural effusion, the ORRs were 50% in the endostar group and 45.4% in the cisplatin group.

Intrapleural therapy of endostar is a safe and effective method for the patients with lung cancer mediated MPE, which shows a higher curative rate than that of cisplatin. The therapeutic effect is more obvious especially for the patients with bloody pleural effusion and the patients with lower CEA values (<100 μg/L) in the pleural effusion. And the endostar group has less adverse reactions and better safety than the cisplatin group. Furthermore, endostar can significantly improve the quality of life of the patients.